Related Experiment Video

Updated: Jun 23, 2026

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome
06:04

Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome

Published on: September 27, 2024

The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study

Alejandra Meaney1, Guillermo Ceballos, Juan Asbun

  • 1Cardiovascular Unit, Regional Hospital, 1 de Octubre, ISSSTE, Mexico. ameaney@cinvestav.mx

Journal of Clinical Pharmacology
|May 16, 2009
PubMed

Insights

This study compared three lipid-lowering therapies in high-risk coronary patients. Dual therapy, combining a statin with ezetimibe, showed a beneficial effect on carotid intima-media thickness, a marker of atherosclerosis.

Area of Science:

  • Cardiology
  • Pharmacology
  • Atherosclerosis Research

Background:

  • High-risk coronary patients often require effective lipid-lowering therapies to reduce cardiovascular risk.
  • Carotid intima-media thickness (IMT) is a validated surrogate marker for atherosclerosis progression.
  • Optimizing lipid-lowering strategies is crucial for managing coronary artery disease.

Purpose of the Study:

  • To assess the effect of three distinct lipid-lowering therapies on carotid intima-media thickness (IMT) reduction in high-risk coronary Mexican patients.
  • To compare the efficacy of pravastatin monotherapy, high-dose simvastatin monotherapy, and a combination of simvastatin and ezetimibe.
  • To evaluate changes in low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (CRP) as secondary endpoints.

Main Methods:

  • A randomized, comparative, open-label clinical trial involving 90 high-risk coronary patients.
  • Patients were assigned to three groups receiving different initial or adjusted lipid-lowering regimens, including pravastatin, simvastatin, and ezetimibe.
  • The primary endpoint was the change in carotid IMT over a 1-year period.

Main Results:

  • All three treatment groups demonstrated a reduction in carotid IMT after 1 year.
  • Mean IMT values decreased from baseline across all groups, with no statistically significant differences between them at study conclusion.
  • Low-density lipoprotein cholesterol (LDL-C) levels were significantly reduced in all groups, with no significant differences observed in CRP, HDL-C, triglycerides, blood pressure, or BMI.

Conclusions:

  • Dual therapy, specifically the combination of a statin with ezetimibe, demonstrated a beneficial effect on carotid intima-media thickness in high-risk coronary patients.
  • The study provides early evidence supporting the efficacy of combination therapy as a valuable strategy for managing atherosclerosis.
  • Further research is warranted to confirm these findings and explore long-term outcomes.

More Related Videos

A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology09:33

A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology

Published on: February 7, 2015

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...